PICO Portalanswers from OpenAlex
Institute of Oncology Prof. Dr. Ion Chiricuta
InstitutionResearch output, impact & collaborations
Institute of Oncology Prof. Dr. Ion Chiricuta is a institution indexed in PICO Portal from OpenAlex.
What is known about Institute of Oncology Prof. Dr. Ion Chiricuta?
PICO Portalrecord summary
Institute of Oncology Prof. Dr. Ion Chiricuta is a research organisation in Cluj-Napoca, RO. OpenAlex records 2,346 works and 123,378 citations for it. 560 researchers list it as their most recent affiliation.
How many works does Institute of Oncology Prof. Dr. Ion Chiricuta have?
PICO Portalindexed works
Institute of Oncology Prof. Dr. Ion Chiricuta has 2,346 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Institute of Oncology Prof. Dr. Ion Chiricuta have?
PICO Portalcitation count
Institute of Oncology Prof. Dr. Ion Chiricuta has 123,378 citations in the OpenAlex counts PICO Portal stores.
How many researchers are at Institute of Oncology Prof. Dr. Ion Chiricuta?
PICO Portalresearcher count
Institute of Oncology Prof. Dr. Ion Chiricuta has 560 researchers in the PICO Portal index.
What is the average h-index at Institute of Oncology Prof. Dr. Ion Chiricuta?
PICO Portalavg h-index
Institute of Oncology Prof. Dr. Ion Chiricuta has an average h-index of 71 in OpenAlex.
What is the ROR of Institute of Oncology Prof. Dr. Ion Chiricuta?
PICO Portalror
The ROR for Institute of Oncology Prof. Dr. Ion Chiricuta is on the source record.
What is the OpenAlex record for Institute of Oncology Prof. Dr. Ion Chiricuta?
PICO Portalopenalex
The OpenAlex for Institute of Oncology Prof. Dr. Ion Chiricuta is on the source record.
Who are the most-cited researchers behind Institute of Oncology Prof. Dr. Ion Chiricuta?
PICO Portaltop researchers by citations
What are the most-cited papers on Institute of Oncology Prof. Dr. Ion Chiricuta?
PICO Portalmost cited works
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu, Eng Huat Tan, Vera Hirsh, Sumitra Thongprasert, Daniel Campos, Savitree Maoleekoonpiroj, Michael Smylie, Renato Martins, Maximiliano Van Kooten, Mircea Dediu, B. Findlay, Dongsheng Tu, D. Johnston, Andrea Bezjak, Gary M. Clark, P. Santabárbara, Lesley Seymour
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
Matthew D. Hellmann, Tudor–Eliade Ciuleanu, Adam Płużański, Jong Seok Lee, Gregory A. Otterson, Clarisse Audigier-Valette, Elisa Minenza, Helena Linardou, Sjaak A. Burgers, Pamela Salman, Hossein Borghaei, Suresh S. Ramalingam, Julie R. Brahmer, Martin Reck, Kenneth J. O’Byrne, William J. Geese, George Green, Chang Han, Joseph D. Szustakowski, Prabhu Bhagavatheeswaran, Diane Healey, Yali Fu, Faith E. Nathan, Luis Paz‐Ares
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
David P. Carbone, Martin Reck, Luis Paz‐Ares, Ben Creelan, Leora Horn, Martin Steins, Enriqueta Felip, Michel M. van den Heuvel, Tudor–Eliade Ciuleanu, Firas Badin, Neal Ready, T. Jeroen N. Hiltermann, Suresh Nair, Rosalyn A. Juergens, Solange Peters, Elisa Minenza, John Wrangle, Delvys Rodríguez‐Abreu, Hossein Borghaei, George R. Blumenschein, Liza C. Villaruz, Libor Havel, Jana Krejčí, Jesus Corral Jaime, Han Chang, William J. Geese, Prabhu Bhagavatheeswaran, Allen C. Chen, Mark A. Socinski
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Edward B. Garon, Tudor–Eliade Ciuleanu, Óscar Arrieta, Kumar Prabhash, Konstantinos N. Syrigos, Tuncay Göksel, Keunchil Park, Vera Gorbunova, Rubén Dario Kowalyszyn, Joanna Pikiel, Grzegorz Czyżewicz, С. В. Орлов, C. Lewanski, Michael Thomas, Paolo Bidoli, Shaker R. Dakhil, Steven Gans, Joo-Hang Kim, Alexandru Grigorescu, Nina Karaseva, Martin Reck, Federico Cappuzzo, Ekaterine Alexandris, Andreas Sashegyi, Sergey Yurasov, M. Pérol
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
Josep Tabernero, Takayuki Yoshino, Allen Lee Cohn, Radka Obermannová, G. Bodoky, Rocio García‐Carbonero, Tudor–Eliade Ciuleanu, David C. Portnoy, Eric Van Cutsem, Axel Grothey, Jana Prausová, Pilar García‐Alfonso, Kentaro Yamazaki, Philip R. Clingan, Sara Lonardi, Tae Won Kim, Lorinda Simms, Shao-Chun Chang, Federico Nasroulah
How much of the research on Institute of Oncology Prof. Dr. Ion Chiricuta is open access?
PICO Portalopen access share
89%OPEN ACCESS